2. Sinovet
• A private research-based company
• Business focus: Animal biological
product development, manufacture,
and marketing
• Company core value: innovation,
quality, and service
4. Fact of Sinovet
Sinovet (Beijing) was established in 2010 after splitting from another
biological company (Headquarter + Marketing)
Sinovet (Jiangsu) was established in 2011 in China Medical City in
Taizhou, Jiangsu ( Production + R&D + Marketing)
Major business units: R&D, Production, and Marketing
Employee: 200 plus
Investment Capital : US$ 30 millions
Revenue (2015) : US$ 10 millions
5. Board of Directors
Wu, Hua
Chairman,
President
Zhao, Jianzeng
Director
Vice-President
Marketing
Wu, Qiong
Director
Vice-President
HR and Finance
Wang, Wei
Secretary,
GM,R&D
Regulatory
Business
Zhang,
Shucheng
Director
Vice-President
Manufacture
and R&D
7. Wu, Hua
President , CEO
Zhao,
Jianzeng
VP, Marketing
Lu, Wei
General Manager,
South China
Regions
Tian, Changxiao
General Manager
Key Customer
Account
Chen, Lei,
General Manager,
North China
Regions
Shi, Xinchuan
General Manager
Bovine Products
Zhang, Shucheng
VP, R&D,
Production
Su, Weiwei,
General Manager,
Sinovet (Jiangsu),
Production, QC, QA
Wang, Wei
General Manager,
R&D RA, Business,
Networking
Xia Mingqi
Associate General M,
R&D Swine Diseases
He, Yanliang
Associate General M,
R&D Small Animal
Diseases
Li, Zhenguang
Associate General M,
R&D Bovine Diseases
Wu, Qiong
VP, HR,
Finance
Wu,Yingying
Associate General
Manager, Finance
Xu, Jianjun
Manager, Human
Resource
Sinovet Leadership Team
8. Milestones of Sinovet
2013
2010
2011
2012 2014 2016
2015
Sinovet
(Beijing)
established
Sinovet (Jiangsu)
established
HP PRRS vaccine
licensed
HP-PRRS/CSF
combo vaccine
clinical trial
Two production
lines accredited
for GMP
HP PRRS-
CSF combo
vaccine
licensed
Two more production lines
accredited for GMP
PRV, HP-PRRS (bioreactor),
BVD licensed
First product (CSF) on market
Sinovet (Jiangsu)
construction
completed
9. R&D Center
Research Teams: 35+ scientists
Research Focus: Animal (swine, bovine, C&A )
vaccines and diagnostic reagents/kits
Key Technologies/resources
Suspension cell technology
Lyophilization/Stabilizer platform
Genetic engineering technology
Network and collaborations
Local strain access and acquisition through surveillance
program
10. R&D Center
R&D Center
Swine
HP–PRRS
Live
PRRS-CSF
Combo
PRRS-CSF-
PRV Combo
PRRS-PRV
combo
SIV
PCV2
Bovine
BVD, Killed
BVD-IBR
Killed
BVD-IBR Live
Bovine Multiple
Combo
Small
Animal
MEV-CDV
live
Bacterial
Vaccines
Rabies
Technology
Suspension
cells
Adjuvant
Vaccine
Processing
Business/
Regulatory
Regulatory
Affairs
IP
Networking
Business and
Legal
Diagnosis
Monoclonal
antibodies
Diagnostic
kits
Tech service
support
15. Innovation Example I
HP-PRRS/CSF Live Combo Vaccine
Innovation Points:
• First PRRS/CSF combo vaccine
• Most safe vaccine HP PRRSV strain with
double gene deletions
• PRRS vaccine strain without
immunosuppression and interference to
other vaccines
• Innovation testing method for CSF final
product
16. Innovation Example II
Suspension Cell Technology
MDCK
Cells
Marc-145
Cells
Adherence Cells Suspension Cells
Highlights:
- Serum free
medium
- No micro-
carrier
- High virus
titer
- Proprietary
technology
17. Intellectual Properties
• Chinese patents
• Published - 12
• Pending application - 4
• International patents
• Published - 3 (filed in 15
countries )
• Pending application - 1
• Trademarks
• Approved - 1
• Pending applications - 25
20. Production Capacity and
Production Lines
Capacity of production facility (400 M)
• Live viral vaccine - 200 million dose
• Killed viral vaccine – 120 million dose
• Killed bacterial vaccine – 80 million dose
GMP-certified production lines
Live virus vaccine (Roller Bottles)
Live virus vaccine (Bioreactors)
Killed virus vaccine (Roller Bottles)
Killed bacterial vaccine (Fermenter)
Production lines to be established
(phase II)
Killed virus vaccine (Bioreactors)
Live bacterial vaccine
24. Product Quality Control
• Experienced
management
Team
• Well-trained
team for each
position
• State-of-art
Facility
• Strictly
enforced GMP
system
Manufacture/
Management
Quality Control Quality
Assurance
• Raw material
• Package
materials
• Antigen batches
and critical
reagents
• Final product
• Regular
environment
monitoring
• Water system
• Manufacture
process and
environment
• Water and gas
supply system
• Product release
process
• Costumer
feedback
• Documentation
system
26. Marketing and Technical Service
Organization
Marketing
Sales
South
China
North
China
Large
Farms
Technical
Service
Tech
Service
Team
Diagnostic
Lab
28. Major Partners and Collaborators
Institute of Veterinary Drug Control
Pfizer (Zoetis) Animal Health
Tiankang Animal Health
China Animal Husbandry Group
29. Government Sponsored Researches
Name of Project Sponsors Funding
Studies on diagnostic technology of cattle and
sheep
MOST US$ 200K
Studies on prevention/control technology of
major infectious diseases of cattle and sheep
MOST US$ 1000K
Stress effect on bovine respiratory diseases MOST US$ 200K
Studies on lyophilization/stabilizer for cattle
vaccines
MOST US$ 500K
Studies on animal vaccine technology MOST US$ 200K
Studies on cell suspension for animal vaccine
development
MOA US$ 170K
Industrialization research on CSF/PRRS
combo vaccine
JPST US$ 900K
PRSSV differential diagnosis JPST US$ 40K
MOST: Ministry of Science and Technology; MOA: Ministry of Agriculture; JPST: Jiangsu Province
Science and Technology Department